![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: AUH |
Gene summary for AUH |
![]() |
Gene information | Species | Human | Gene symbol | AUH | Gene ID | 549 |
Gene name | AU RNA binding methylglutaconyl-CoA hydratase | |
Gene Alias | AUH | |
Cytomap | 9q22.31 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q13825 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
549 | AUH | CCI_2 | Human | Cervix | CC | 1.44e-11 | 1.19e+00 | 0.5249 |
549 | AUH | CCI_3 | Human | Cervix | CC | 8.65e-20 | 1.05e+00 | 0.516 |
549 | AUH | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.61e-11 | -5.27e-01 | 0.0155 |
549 | AUH | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.31e-03 | -5.02e-01 | -0.1207 |
549 | AUH | HTA11_696_2000001011 | Human | Colorectum | AD | 5.05e-08 | -3.60e-01 | -0.1464 |
549 | AUH | HTA11_866_3004761011 | Human | Colorectum | AD | 1.18e-04 | -4.29e-01 | 0.096 |
549 | AUH | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.17e-02 | -4.65e-01 | 0.0338 |
549 | AUH | HTA11_7696_3000711011 | Human | Colorectum | AD | 5.71e-06 | -3.54e-01 | 0.0674 |
549 | AUH | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.00e-03 | -5.89e-01 | 0.2585 |
549 | AUH | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.38e-07 | -4.33e-01 | 0.3005 |
549 | AUH | A015-C-203 | Human | Colorectum | FAP | 6.55e-24 | -2.53e-01 | -0.1294 |
549 | AUH | A015-C-204 | Human | Colorectum | FAP | 1.27e-05 | -1.84e-01 | -0.0228 |
549 | AUH | A014-C-040 | Human | Colorectum | FAP | 1.97e-03 | -3.59e-01 | -0.1184 |
549 | AUH | A002-C-201 | Human | Colorectum | FAP | 1.05e-11 | -2.48e-01 | 0.0324 |
549 | AUH | A002-C-203 | Human | Colorectum | FAP | 1.34e-03 | -1.53e-02 | 0.2786 |
549 | AUH | A001-C-119 | Human | Colorectum | FAP | 4.93e-03 | -2.38e-01 | -0.1557 |
549 | AUH | A001-C-108 | Human | Colorectum | FAP | 5.92e-14 | -8.45e-02 | -0.0272 |
549 | AUH | A002-C-205 | Human | Colorectum | FAP | 1.50e-19 | -3.37e-01 | -0.1236 |
549 | AUH | A001-C-104 | Human | Colorectum | FAP | 1.46e-03 | 5.25e-03 | 0.0184 |
549 | AUH | A015-C-005 | Human | Colorectum | FAP | 4.27e-02 | -1.97e-01 | -0.0336 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0044282 | Colorectum | AD | small molecule catabolic process | 118/3918 | 376/18723 | 1.05e-06 | 3.55e-05 | 118 |
GO:0006635 | Colorectum | AD | fatty acid beta-oxidation | 33/3918 | 74/18723 | 3.98e-06 | 1.09e-04 | 33 |
GO:0009062 | Colorectum | AD | fatty acid catabolic process | 41/3918 | 100/18723 | 4.02e-06 | 1.09e-04 | 41 |
GO:0019395 | Colorectum | AD | fatty acid oxidation | 40/3918 | 103/18723 | 2.43e-05 | 4.69e-04 | 40 |
GO:0016042 | Colorectum | AD | lipid catabolic process | 97/3918 | 320/18723 | 4.31e-05 | 7.56e-04 | 97 |
GO:0006631 | Colorectum | AD | fatty acid metabolic process | 114/3918 | 390/18723 | 5.58e-05 | 9.44e-04 | 114 |
GO:0072329 | Colorectum | AD | monocarboxylic acid catabolic process | 44/3918 | 122/18723 | 8.05e-05 | 1.28e-03 | 44 |
GO:0034440 | Colorectum | AD | lipid oxidation | 40/3918 | 108/18723 | 8.52e-05 | 1.32e-03 | 40 |
GO:0030258 | Colorectum | AD | lipid modification | 67/3918 | 212/18723 | 1.66e-04 | 2.27e-03 | 67 |
GO:0009083 | Colorectum | AD | branched-chain amino acid catabolic process | 10/3918 | 15/18723 | 1.68e-04 | 2.29e-03 | 10 |
GO:0016054 | Colorectum | AD | organic acid catabolic process | 73/3918 | 240/18723 | 3.20e-04 | 3.81e-03 | 73 |
GO:0044242 | Colorectum | AD | cellular lipid catabolic process | 66/3918 | 214/18723 | 3.96e-04 | 4.50e-03 | 66 |
GO:0046395 | Colorectum | AD | carboxylic acid catabolic process | 70/3918 | 236/18723 | 9.06e-04 | 8.71e-03 | 70 |
GO:0006520 | Colorectum | AD | cellular amino acid metabolic process | 81/3918 | 284/18723 | 1.37e-03 | 1.19e-02 | 81 |
GO:0009081 | Colorectum | AD | branched-chain amino acid metabolic process | 10/3918 | 19/18723 | 2.25e-03 | 1.77e-02 | 10 |
GO:00090831 | Colorectum | MSS | branched-chain amino acid catabolic process | 10/3467 | 15/18723 | 5.64e-05 | 9.87e-04 | 10 |
GO:00090622 | Colorectum | MSS | fatty acid catabolic process | 32/3467 | 100/18723 | 8.28e-04 | 8.67e-03 | 32 |
GO:00090811 | Colorectum | MSS | branched-chain amino acid metabolic process | 10/3467 | 19/18723 | 8.39e-04 | 8.68e-03 | 10 |
GO:00442822 | Colorectum | MSS | small molecule catabolic process | 94/3467 | 376/18723 | 9.85e-04 | 9.86e-03 | 94 |
GO:00302582 | Colorectum | MSS | lipid modification | 57/3467 | 212/18723 | 1.64e-03 | 1.49e-02 | 57 |
Page: 1 2 3 4 5 6 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00280 | Colorectum | AD | Valine, leucine and isoleucine degradation | 25/2092 | 48/8465 | 3.97e-05 | 3.41e-04 | 2.18e-04 | 25 |
hsa002801 | Colorectum | AD | Valine, leucine and isoleucine degradation | 25/2092 | 48/8465 | 3.97e-05 | 3.41e-04 | 2.18e-04 | 25 |
hsa002804 | Colorectum | FAP | Valine, leucine and isoleucine degradation | 18/1404 | 48/8465 | 3.94e-04 | 3.06e-03 | 1.86e-03 | 18 |
hsa002805 | Colorectum | FAP | Valine, leucine and isoleucine degradation | 18/1404 | 48/8465 | 3.94e-04 | 3.06e-03 | 1.86e-03 | 18 |
hsa002809 | Esophagus | ESCC | Valine, leucine and isoleucine degradation | 34/4205 | 48/8465 | 2.34e-03 | 6.54e-03 | 3.35e-03 | 34 |
hsa0028014 | Esophagus | ESCC | Valine, leucine and isoleucine degradation | 34/4205 | 48/8465 | 2.34e-03 | 6.54e-03 | 3.35e-03 | 34 |
hsa002806 | Liver | NAFLD | Valine, leucine and isoleucine degradation | 20/1043 | 48/8465 | 3.03e-07 | 1.65e-05 | 1.33e-05 | 20 |
hsa0028011 | Liver | NAFLD | Valine, leucine and isoleucine degradation | 20/1043 | 48/8465 | 3.03e-07 | 1.65e-05 | 1.33e-05 | 20 |
hsa0028021 | Liver | Cirrhotic | Valine, leucine and isoleucine degradation | 32/2530 | 48/8465 | 1.45e-07 | 2.02e-06 | 1.24e-06 | 32 |
hsa0028031 | Liver | Cirrhotic | Valine, leucine and isoleucine degradation | 32/2530 | 48/8465 | 1.45e-07 | 2.02e-06 | 1.24e-06 | 32 |
hsa0028041 | Liver | HCC | Valine, leucine and isoleucine degradation | 41/4020 | 48/8465 | 4.84e-08 | 7.05e-07 | 3.92e-07 | 41 |
hsa0028051 | Liver | HCC | Valine, leucine and isoleucine degradation | 41/4020 | 48/8465 | 4.84e-08 | 7.05e-07 | 3.92e-07 | 41 |
hsa002807 | Prostate | Tumor | Valine, leucine and isoleucine degradation | 20/1791 | 48/8465 | 1.03e-03 | 4.59e-03 | 2.84e-03 | 20 |
hsa0028012 | Prostate | Tumor | Valine, leucine and isoleucine degradation | 20/1791 | 48/8465 | 1.03e-03 | 4.59e-03 | 2.84e-03 | 20 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AUH | SNV | Missense_Mutation | rs529693736 | c.1004G>A | p.Arg335His | p.R335H | Q13825 | protein_coding | tolerated(0.25) | benign(0.001) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AUH | SNV | Missense_Mutation | c.554N>T | p.Gly185Val | p.G185V | Q13825 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-05-4418-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
AUH | SNV | Missense_Mutation | novel | c.401N>A | p.Pro134Gln | p.P134Q | Q13825 | protein_coding | deleterious(0.04) | possibly_damaging(0.83) | TCGA-49-6761-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
AUH | SNV | Missense_Mutation | c.893A>G | p.Glu298Gly | p.E298G | Q13825 | protein_coding | deleterious(0.03) | probably_damaging(0.974) | TCGA-69-7765-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | SD | |
AUH | SNV | Missense_Mutation | c.853N>T | p.Ala285Ser | p.A285S | Q13825 | protein_coding | deleterious(0.02) | probably_damaging(0.929) | TCGA-37-4135-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
AUH | SNV | Missense_Mutation | novel | c.718N>T | p.Ala240Ser | p.A240S | Q13825 | protein_coding | tolerated(0.12) | possibly_damaging(0.888) | TCGA-58-8388-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
AUH | SNV | Missense_Mutation | rs529693736 | c.1004G>A | p.Arg335His | p.R335H | Q13825 | protein_coding | tolerated(0.25) | benign(0.001) | TCGA-MF-A522-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
AUH | SNV | Missense_Mutation | rs776409546 | c.499N>A | p.Asp167Asn | p.D167N | Q13825 | protein_coding | tolerated(0.11) | benign(0.006) | TCGA-D6-6516-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
AUH | SNV | Missense_Mutation | c.907N>G | p.Thr303Ala | p.T303A | Q13825 | protein_coding | deleterious(0.03) | benign(0.391) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
AUH | SNV | Missense_Mutation | rs773262900 | c.712N>C | p.Phe238Leu | p.F238L | Q13825 | protein_coding | deleterious(0.02) | probably_damaging(0.979) | TCGA-CD-8529-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | epirubicin | CR |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |